Cytek Biosciences
CTKB
105 hedge funds and large institutions have $720M invested in Cytek Biosciences in 2023 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 44 increasing their positions, 29 reducing their positions, and 19 closing their positions.
68% more capital invested
Capital invested by funds: $428M → $720M (+$292M)
52% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 29
1.47% more ownership
Funds ownership: 56.77% → 58.23% (+1.5%)
1% less funds holding
Funds holding: 106 → 105 (-1)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $152K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.35M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.11M |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
+$3.78M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.86M |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$9.72M |
| 2 |
Millennium Management
New York
|
-$2.36M |
| 3 |
Renaissance Technologies
New York
|
-$1.64M |
| 4 |
SG Americas Securities
New York
|
-$1.04M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$971K |
CTKB Hedge Fund Activity: Q4 2023 in Review
105 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q4 2023, worth a combined $720M — up 68% from $428M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of CTKB and 18 opened new positions — a net loss of 1 holder — while 29 trimmed existing stakes and 44 added.
The largest buyer was BlackRock, adding an estimated $6.35M. The largest seller was Brown Capital Management, cutting an estimated $9.72M.
- 105 institutional investors held Cytek Biosciences (CTKB) as of Q4 2023, down from 106 in Q3 2023.
- Funds reported $720M of Cytek Biosciences stock for Q4 2023, up 68% quarter-over-quarter.
- 18 funds opened new Cytek Biosciences positions in Q4 2023 and 19 closed out, a net change of -1 holder.
- The largest Cytek Biosciences buyer in Q4 2023 was BlackRock, an estimated $6.35M added.
- The largest Cytek Biosciences seller in Q4 2023 was Brown Capital Management, an estimated $9.72M sold.
Based on aggregated 13F filings for Q4 2023.